DOCSLIB.ORG

Novel Tetracyclic Compounds Having Anti-Allergic and Anti-Asthmatic Activities, Their Preparation and Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Tetracyclic Compounds Having Anti-Allergic and Anti-Asthmatic Activities, Their Preparation and Use Europaisches Patentamt European Patent Office © Publication number: 0 505 014 A2 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 92201652.2 int. Ci.5; C07D 487/04, C07D 471/14, A61K 31/55, //(C07D487/04, @ Date of filing: 05.10.90 241 :00,223:00),(C07D471/14, 241 :00,223:00,221 :00) This application was filed on 06 - 06 - 1992 as a Shinagawa-ku, Tokyo 140(JP) divisional application to the application Inventor: Sakamoto, Toshiaki, c/o Sankyo mentioned under INID code 60. Company Limited No. 2-58, 1-chome, Hiromachi ® Priority: 05.10.89 JP 260592/89 Shinagawa-ku, Tokyo 140(JP) 29.03.90 JP 81513/89 Inventor: Sugiyama, Mitsuo, c/o Sankyo Company Limited @ Date of publication of application: No. 2-58, 1-chome, Hiromachi 23.09.92 Bulletin 92/39 Shinagawa-ku, Tokyo 140(JP) Inventor: lizuka, Yoshio, c/o Sankyo Company © Publication number of the earlier application in Limited accordance with Art.76 EPC: 0 421 823 No. 2-58, 1-chome, Hiromachi Shinagawa-ku, Tokyo 140(JP) © Designated Contracting States: Inventor: Yamaguchi, Takeshi, c/o Sankyo AT BE CH DE DK ES FR GB GR IT LI LU NL SE Company Limited No. 2-58, 1-chome, Hiromachi © Applicant: Sankyo Company Limited Shinagawa-ku, Tokyo 140(JP) 5-1 Nihonbashi Honcho 3-chome Chuo-ku Tokyo(JP) © Representative: Gibson, Christian John Robert @ Inventor: Fukumi, Hiroshi, c/o Sankyo et al Company Limited MARKS & CLERK 57/60 Lincoln's Inn Fields No. 2-58, 1-chome, Hiromachi London WC2A 3LS(GB) © Novel tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use. © Compounds of formula (I): CM o Rank Xerox (UK) Business Services EP 0 505 014 A2 H H C C // \ // \ HC C-CH2-C CH R2. II I II HC C C CH V / \ / \\ X , Q N-CH C R1 (I) / \ H H2C CH2 \ / H2C-N \ R3 [in which: Q is nitrogen or =CH-; R1 and R2 are hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl or halogen; and R3 is various specific substituted alkyl groups] and pharmaceutically acceptable salts thereof have valuable anti- allergic and anti-asthmatic activities. They may be prepared by reacting a corresponding compound where R3 is replaced by a hydrogen atom with a compound to introduce the group R3. 2 EP 0 505 014 A2 The present invention relates to a new series of tetracyclic compounds having two or three ring nitrogen atoms, which we have found to have valuable anti-allergic and anti-asthmatic activities, and provides methods and compositions using them, as well as processes for their preparation. The compounds of the present invention may be generally described as dibenzo-pyrazino-azepine or benzo-pyrido-pyrazino-azepine derivatives. Certain compounds of this type are known. For example, mianserin, which has the formula (A): H H C C / \ / \ HC C-CH2-C CH I II I II HC C C CH \ / \ / \ / HC N-CH CH (A) / \ H2C CH2 \ / H2C-N \ CH3 25 mirtazapine, which has the formula (B): H H 30 C C II \ II \ HC C-CH2-C CH I II I II HC C C CH 35 \\ / \ / \ / N N-CH CH (B) / \ H2C CH2 \ / 40 H2C-N \ CH3 45 aptazapine, which has the formula (C): 50 55 3 EP 0 505 014 A2 H C / \ HC C-CH2-N CH I II I II HC C C CH (C) \ / \ / \ / HC N-CH CH / \ H2C CH2 \ / H2C-N \ CH3 2-(2-hydroxyethyl)-1 ,3,4,1 4b-tetrahydro-2H,1 0H-pyrazino[1 ,2-a]pyrrolo[2,1 -c][1 ,4]benzodiazepine, which has the formula (D): H C / \ HC C-CH2-N CH I II I II HC C C CH (D) \\ / \ I \ I HC N-CH CH / \ H2C CH2 \ / H2C-N \ CH2CH2OH 2-methoxycarbonylmethyl-1 ,3,4,1 4b-tetrahydro-2H,1 0H-pyrazino[1 ,2-a]pyrrolo[2,1 -c][1 ,4]benzodiazepine, which has the formula (E): H C / \ HC C-CH2-N CH I II I II HC C C CH (E) \ / \ / \ / HC N-CH CH / \ H2C CH2 \ / H2C-N \ CH2COOCH3 and 2-(2-carboxamidoethyl)-1 ,2,3,4,1 0,1 4b-hexahydrodibenzo[c,f]pyrazino[1 ,2-a]azepine, which has the for- EP 0 505 014 A2 mula (F): H C C // \ / \ HC C-CH2-C CH I II I II HC C C CH \ 10 / \ / \ / HC N-CH CH (F) / \ H2C CH2 \ / 15 H2C-N \ CH2CH2CONH2 20 are disclosed in US Patent Specification No. 4 025 513, US Patent Specification No. 4 062 848, European Patent Specification No. 1585 and PCT Application No. WO-88/07997, and are said to have various activities, including anti-depressant activity and anti-histamine activity. The compounds referred to above which are said to possess an anti-allergic activity have been found to be not entirely satisfactory, in that the intensity of the activity is less than would be desired for a useful 25 commercial product, and side effects, such as irritation or depression of the central nervous system, often occur. It would, therefore, be desirable to develop therapeutic agents which, whilst possessing excellent anti-histamic, anti-allergic and anti-asthmatic activities, also have no substantial adverse reactions, such as depression or irritation of the central nervous system. We have now discovered a series of tetracyclic compounds which fulfil these various desiderata. 30 The compounds of the present invention are those compounds of formula (I): H H C C 35 / \ // \ HC C-CH2-C CH R2. HC C C CH \\ / \ / \ X , 40 Q N-CH C R1 (i: / \ H H2C CH2 \ / H2C-N 45 \ R3 in which: 50 Q represents a nitrogen atom or a group of formula = CH-; R1 and R2 are the same or different and each represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 1 to 6 carbon atoms, a hydroxy group, a trifluoromethyl group or a halogen atom; R3 represents: 55 a substituted alkyl group having from 3 to 7 carbon atoms and substituted by at least one substituent selected from hydroxy groups and groups of formula -COOR4, where R+ represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, an aryl group, as defined below, or an aralkyl group, as defined below; 5 EP 0 505 014 A2 a group of formula -B-O-D-OR4, where: B represents an alkylene or alkylidene group having from 2 to 4 carbon atoms; D represents an alkylene or alkylidene group having from 2 to 7 carbon atoms or such an alkylene or alkylidene group in which the carbon chain is interrupted by 1 or 2 oxygen atoms; and R+ is as defined above; 5 a group of formula -E-O-G-COOR4, where: E represents an alkylene or alkylidene group having from 2 to 7 carbon atoms; G represents a direct carbon-carbon single bond, an alkylene or alkylidene group having from 1 to 9 carbon atoms or such an alkylene or alkylidene group in which the carbon chain is interrupted by 1 or 2 oxygen atoms, said alkylene or alkylidene group being unsubstituted or being substituted by an aryl group; and R+ is as defined above; io a group of formula -E-0-G-CONR5RG, where: E and G are as defined above; and R5 and RG are the same or different and each represents a hydrogen atom, an unsubstituted alkyl group having from 1 to 6 carbon atoms, a substituted alkyl group which has from 1 to 6 carbon atoms and which is substituted by at least one is of substituents (a), defined below, a cycloalkyl group which has from 3 to 7 ring carbon atoms and which is unsubstituted or is substituted by at least one alkyl group having from 1 to 4 carbon atoms, an aryl group, as defined below, or an aralkyl group, as defined below; or R5 and RG, together with the nitrogen atom to which they are attached, represent a cyclic amino 20 group having from 3 to 6 ring atoms, of which one is said nitrogen atom, 0 or 1 is an additional nitrogen and/or oxygen and/or sulphur hetero-atom and the remainder are carbon atoms, said heterocyclic group being unsubstituted or being substituted by at least one of substituents (c), defined below; or a group of formula -J-CH(OH)-CH2R7, where: J represents an alkylene or alkylidene group having from 1 to 4 carbon atoms; and R7 represents a hydroxy group, a halogen atom or a group of formula -NR5RG, 25 where R5 and RG are as defined above; said aralkyl groups are alkyl groups having from 1 to 4 carbon atoms, which are substituted by from 1 to 3 aryl groups, as defined below; said aryl groups have from 6 to 10 ring carbon atoms and are unsubstituted or are substituted by at least one of substituents (b), defined below; 30 substituents (a): amino groups; alkylamino groups in which the alkyl group has from 1 to 6 carbon atoms; dialkylamino groups in which the alkyl groups are the same or different and each has from 1 to 6 carbon atoms; and 35 cyclic amino groups having from 3 to 6 ring atoms, of which one is a nitrogen atom, 0 or 1 is an additional nitrogen and/or oxygen and/or sulphur hetero-atom and the remainder are carbon atoms, said heterocyclic group being unsubstituted or being substituted by at least one of substituents (c), defined below; substituents (b): 40 alkyl groups having from 1 to 6 carbon atoms; alkoxy groups having from 1 to 6 carbon atoms; aryl groups, as defined above, provided that they are not themselves substituted by aryl groups; and halogen atoms; 45 substituents (c): alkyl groups having from 1 to 4 carbon atoms; aryl groups, as defined above; and aralkyl groups, as defined above; and pharmaceutically acceptable salts thereof.
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0192302 A1 Hsu Et Al
    US 2002O1923O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0192302 A1 Hsu et al. (43) Pub. Date: Dec. 19, 2002 (54) TRANSDERMAL AND TOPICAL which is a continuation-in-part of application No. ADMINISTRATION OF ANTIDEPRESSANT 09/569,889, filed on May 11, 2000, which is a con DRUGS USING BASIC ENHANCERS tinuation-in-part of application No. 09/465,098, filed on Dec. 16, 1999, and which is a continuation-in-part (76) Inventors: Tsung-Min Hsu, San Diego, CA (US); of application No. 09/738,395, filed on Dec. 14, 2000, Alan T. J. Hickey, San Diego, CA which is a continuation-in-part of application No. (US); Eric C. Luo, Plano, TX (US); 09/607,892, filed on Jun. 30, 2000, now abandoned. Jane Obara, San Diego, CA (US) Publication Classification Correspondence Address: REED & ASSOCATES (51) Int. Cl." .......................... A61K 33/02; A61K 33/00 800 MENLO AVENUE (52) U.S. Cl. ............................................ 424/719, 424/722 SUTE 210 MENLO PARK, CA 94025 (US) (57) ABSTRACT (21) Appl. No.: 10/175,769 Methods are provided for enhancing the permeability of skin (22) Filed: Jun. 19, 2002 or mucosal tissue to topical or transdermal application of antidepressant drugs. The methods entail the use of a base in Related U.S. Application Data order to increase the flux of the drug through a body Surface while minimizing the likelihood of skin damage, irritation or (63) Continuation-in-part of application No. 09/972,008, Sensitization. The permeation enhancer can be an inorganic filed on Oct. 4, 2001, which is a continuation-in-part or organic base.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
    www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0229941A1 Hassman Et Al
    US 2004O229941A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0229941A1 HaSSman et al. (43) Pub. Date: Nov. 18, 2004 (54) ANALEPTIC AND ANTIDEPRESSANT Related U.S. Application Data COMBINATIONS (60) Provisional application No. 60/469,989, filed on May (75) Inventors: Howard A. Hassman, Moorestown, NJ 13, 2003. (US); Rodney J. Hughes, Kennett Square, PA (US) Publication Classification Correspondence Address: (51) Int. Cl." ...................... A61K 31/343; A61K 31/137 CEPHALON, INC. (52) U.S. Cl. ........................... 514/469; 514/617; 514/649 145 BRANDY WINE PARKWAY WEST CHESTER, PA 19380-4245 (US) (57) ABSTRACT (73) Assignee: Cephalon, Inc., West Chester, PA (21) Appl. No.: 10/844,134 Compositions and methods for the treatment of depressive disorders through the administration of modafinil with anti (22) Filed: May 12, 2004 depressants. US 2004/0229941 A1 Nov. 18, 2004 ANALEPTIC AND ANTIDEPRESSANT nocturnal Sleep. Pathological Somnolence, whether due to COMBINATIONS narcolepsy or other causes, is disabling and potentially dangerous. Causes of pathological Somnolence, other than BACKGROUND OF THE INVENTION narcolepsy, include chronic Sleep loSS; Sleep apnea; and other sleep disorders. Whether due to narcolepsy or other 0001) 1. Modafinil causes, pathological Somnolence produces episodes of unin 0002 Modafinil, CHNOS, also known as 2-(benzhy tended sleep, reduced attention, and performance errors. drylsulfinyl) acetamide, or 2-(diphenylmethyl) sulfinyl Consequently, it is linked to a variety of transportation and acetamide, is a Synthetic acetamide derivative with wake industrial accidents. A therapeutic agent that reduces or promoting activity, the Structure of which has been described eliminateS pathological Somnolence would have important in French Patent No.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • Use of Isoindoles for the Treatment of Neurobehavioral Disorders
    (19) TZZ¥_Z¥_T (11) EP 3 156 053 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.04.2017 Bulletin 2017/16 A61K 31/4035 (2006.01) A61P 25/00 (2006.01) (21) Application number: 16200855.1 (22) Date of filing: 04.06.2009 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • KOVACS, Bruce HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Long Beach, CA California 90803 (US) PT RO SE SI SK TR • PINEGAR, Laura Long Beach, CA California 90803 (US) (30) Priority: 20.06.2008 US 74500 (74) Representative: Petty, Catrin Helen et al (62) Document number(s) of the earlier application(s) in Venner Shipley LLP accordance with Art. 76 EPC: 200 Aldersgate 09767450.1 / 2 307 011 London EC1A 4HD (GB) (71) Applicant: Afecta Pharmaceuticals, Inc. Remarks: Irvine, CA 92612 (US) This application was filed on 28-11-2016 as a divisional application to the application mentioned under INID code 62. (54) USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS (57) The present invention generally relates to the disorder and/or treatment or prevention of symptoms of use of drugs for the treatment of neurobehavioral disor- a neurobehavioral disorder by administering suitable Iso- ders or symptoms of a neurobehavioral disorder associ- indole derivatives alone or in combination with other ated with dysfunction of the trimonoamine modulating agents so as to provide relatively equal inhibitory effect system (TMMS). More specifically, the invention de- on serotonin, dopamine and norepinephrine transport- scribes methods for the treatment of a neurobehavioral ers.
    [Show full text]